Details checkedStatus confirmedHistorical/discontinuedCheckedtrial

PIPE-505 by Pipeline Therapeutics

Also known as: PIPE-505

Contineum Therapeutics

Primary source

Company

Contineum Therapeutics

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 1/2

Status

Completed

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

86%

Status Confidence

Status confirmed

Evidence Strength

Needs more support

Last Reviewed

2026-05-31

Geography

United States

Population

adult

Trial IDs

Mechanism

Gamma-secretase inhibitor program intended to promote synaptic/neuroregenerative repair in sensorineural hearing loss with speech-in-noise impairment.

Indications

Hearing Loss Sensorineural Hearing Loss Hidden Hearing Loss Cochlear Synaptopathy

Notes

Important hidden-hearing-loss/speech-in-noise program; the Phase 1/2a study completed, but no onward clinical hearing program has been publicly advanced by the successor company.

Evidence & Sources

3 structured sources

clinicaltrials

Supports: canonicalName, trialIds, stage, route, indications, populationTags, geography

IDs: NCT04462198

Open

company

Supports: company, allCompanies, aliases, mechanism, notes

IDs: PIPE-505

Open

company

Supports: status, notes